Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia

NCT02234752 | Terminated Phase 2 Results DMC

• 1 other identifier: SPHS IRB # 604148-4
• Study Type: interventional
• Target: 3
• Locations: 1 country
• Sites: 1

Brief Summary

Aim: To examine the efficacy of the combination of galantamine and memantine for the treatment of cognitive deficits in outpatients with schizophrenia. Hypothesis: A combination of galantamine and memantine will improve cognitive impairments in patients with schizophrenia. This is an open-label study to evaluate whether a six week course of galantamine ER and memantine XR is effective in improving the cognitive performance of patients with schizophrenia or schizoaffective disorder. The primary outcome measure will be the change in level of cognition as measured by the MATRICS Consensus Cognitive Battery (MCCB). The results of the MATRICS collaborative project recommended the need for standardized cognitive tests that better distinguish the different facets of cognitive dysfunction in schizophrenia. The MCCB will assess the following seven domains: attention/vigilance, reasoning and problem solving, processing speed, social cognition, verbal learning and memory, visual learning and memory, and working memory. The MCCB will be administered at baseline and at the end of the study. We will report total score and each domain score in the MCCB at baseline and six weeks.

Conditions

Schizophrenia; Schizoaffective Disorder

Keywords

Schizophrenia; Schizoaffective Disorder; Cognition; Cognitive Impairment; Galantamine; Memantine

Outcome Measures

Primary Outcomes (1)

• Change in Level of Cognition

  The primary outcome measure will be the change in level of cognition as measured by the MATRICS Consensus Cognitive Battery (MCCB). In schizophrenia, usual composite scores are 20-39. In healthy controls, usual composite scores are normalized to 40-60. Higher values of composite scores mean better cognition. Test scores are normalized to healthy controls, therefore no min-max range is available. Final scores calculated by MATRICS Consensus Cognitive Battery software. Exact minimum/maximum are not known to provider. Overall composite scores are reported.

  Baseline and 6-Weeks

Secondary Outcomes (7)

• Free Tryptophan (TRP)

  Baseline and 6-Weeks

• Kynurenic Acid (KYNA)

  Baseline and 6-Weeks

• Kynurenine (KYN)

  Baseline and 6-Weeks

• Picolinic Acid (PIC)

  Baseline and 6-Weeks

• KYN/TRP

  Baseline and 6-Weeks

Study Arms (1)

Galantamine ER, Memantine XR

EXPERIMENTAL

Week 1, Galantamine ER 8 mg HS \& Memantine XR 7 mg HS Week 2, Galantamine ER 16 mg HS \& Memantine XR 14 mg HS Weeks 3-6, Galantamine ER 24 mg HS \& Memantine XR 21 mg HS

Drug: Galantamine ER; Drug: Memantine XR

Interventions

Galantamine ER DRUG

Also known as: Razadyne, Razadyne ER, Formerly known as Reminyl

Galantamine ER, Memantine XR

Memantine XR DRUG

Also known as: Namenda

Galantamine ER, Memantine XR

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Be male or female aged 18 to 55 years (inclusive).
• Have a DSM-5 diagnosis of schizophrenia or schizoaffective disorder confirmed by medical records. Duration of illness must be ≥ 1year.
• Be clinically stable for at least two months (i.e., has no more than a "moderately severe" severity rating on the following BPRS items: hallucination, unusual thought content and conceptual disorganization.
• Have not had a psychiatric hospitalization in the two months prior to screening.
• Be taking any 1st generation antipsychotic prescribed in the absence of a concomitant anticholinergic or 2nd generation antipsychotic and minimal extrapyramidal symptoms
• Have a Simpson-Angus Score (SAS) \< 6
• Be on current medication regimen for at least six weeks before screening at stable dose and frequency for at least 30 days before screening.
• Be in good general health and expected to complete the clinical study as designed.
• Subjects of childbearing potential must agree to use two forms of non-hormonal contraception (dual contraception) consistently during the screening and treatment periods of the trial, and for 30 days after the final dose of the study medications.
• Females of child-bearing potential must have a negative urine pregnancy test at baseline. This may also be done at subsequent visits if subject reports possibility of pregnancy.
• Have a negative urine drug screen at screening. This may be repeated at the discretion of the primary investigator.
• Have adequate hearing, vision, and language skills to perform the procedures specified in the protocol.
• Be capable of providing informed consent and have voluntarily provided informed consent.

You may not qualify if:

• Have an active, clinically significant unstable medical condition with 30 days prior to screening.
• Have dementia.
• Are pregnant, breastfeeding, or planning to become pregnant
• Are taking or thinking about taking oral contraceptives or an injectable contraceptive.
• Are taking benztropine at a dose greater than 2 mg daily.
• Have a history of Pervasive Development Disorder.
• Have a history of significant head injury/trauma (defined by one of more of the following: loss of consciousness for more than one hour; recurring seizures resulting from the head injury; and/or clear cognitive sequelae of the injury requiring cognitive rehabilitation.)
• Have an allergy to anticholinesterase medications (galantamine, rivastigimine, donepezil) and memantine
• Have a DSM-5 diagnosis of alcohol and/or substance use disorder (other than caffeine and tobacco) within the last 6 months.
• Are taking a restricted medication: Amitriptyline, Doxepin, Imipramine, Flexeril, Clozapine, and/or cortisol (any oral, injectable, or topical steroid medication)
• Have a history of seizures excluding a childhood febrile seizure
• Have received ECT within the last three months prior to screening.
• Have participated in a clinical trial of any other psychotropic medication within last two months prior to screening.
• Have a "severe" or "extremely severe" severity rating on the BPRS items: hallucination or unusual thought content.
• Have more than a "moderate" severity rating on the BPRS item conceptual disorganization .

Sponsors & Collaborators

• Sheppard Pratt Health System: lead

Study Sites (1)

Sheppard Pratt Health System

Baltimore, Maryland, 21204, United States

Location

Related Publications (3)

• Koola MM, Buchanan RW, Pillai A, Aitchison KJ, Weinberger DR, Aaronson ST, Dickerson FB. Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. Schizophr Res. 2014 Aug;157(1-3):84-9. doi: 10.1016/j.schres.2014.04.037. Epub 2014 May 28.

  PMID: 24878431 BACKGROUND

• Koola MM. Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine. Schizophr Res Cogn. 2016 Jun;4:4-9. doi: 10.1016/j.scog.2016.02.001.

  PMID: 27069875 BACKGROUND

• Koola MM, Sklar J, Davis W, Nikiforuk A, Meissen JK, Sawant-Basak A, Aaronson ST, Kozak R. Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments. Schizophr Res. 2018 Mar;193:459-460. doi: 10.1016/j.schres.2017.07.005. Epub 2017 Jul 11. No abstract available.

  PMID: 28705532 RESULT

MeSH Terms

Conditions

Schizophrenia; Psychotic Disorders; Cognitive Dysfunction

Interventions

Galantamine; Memantine

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Cognition Disorders; Neurocognitive Disorders

Intervention Hierarchy (Ancestors)

Amaryllidaceae Alkaloids; Alkaloids; Heterocyclic Compounds; Benzazepines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Amantadine; Adamantane; Bridged-Ring Compounds; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals

Results Point of Contact

• Title: Maju Koola
• Organization: George Washington University, Washington, DC

majumkoola@gmail.com

678-200-8613

Study Officials

• Maju M. Koola, MD

  Sheppard Pratt Health System

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: September 4, 2014
• First Posted: September 9, 2014
• Study Start: September 1, 2014
• Primary Completion: July 1, 2016
• Study Completion: July 1, 2016
• Last Updated: November 9, 2017
• Results First Posted: November 9, 2017

Record last verified: 2016-10

Locations

US (1)